Early career researcher Andréanne Lupien is part of a winning project in the 2024 McGill Innovation Fund competition
SOURCE: McGill Reporter and RI-MUHC
April 5, 2024
Andréanne Lupien, PhD, a junior scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), is among the researchers with projects funded this year by the McGill Innovation Fund (MIF). The 2024 edition of the MIF also featured a supplemental award from the McGill Antimicrobial Resistance Centre (AMR), offered to selected teams thanks to a donation from Rio Tinto.
The MIF-AMR awards provide additional matching funding to support the commercialization of research by teams that develop innovations with the potential to prevent, diagnose or treat serious microbial infections and curb the threat of antimicrobial resistance. Profs. Karine Auclair (McGill University) and Andréanne Lupien (RI-MUHC) received support for their “Itaconate” project, and Prof. Parisa Ariya and her team (McGill University) for their “Patholyzer” project.
A new member of the Infectious Diseases and Immunity in Global Health Program at the RI‑MUHC, Andréanne Lupien’s research focuses on evaluating and developing new treatments against tuberculosis and non-tuberculous mycobacterial infections.
Related news
Third running of the MIF turns focus to antimicrobial resistance, McGill Reporter
Developing technology for fight against antimicrobial resistance